Seres Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
MCRB$1.70-14.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference · Filed/ | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Description | Form | File No. | Exhibit | FilingDate | FurnishedHerewith |
| 3.1 | Restated Certificate of Incorporation, filed on July 1, 2015 | 8-K | 001-37465 | 3.1 | 7/1/15 | |
| 3.2 | Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated June 27, 2023 | 8-K | 001-37465 | 3.1 | 6/28/23 | |
| 3.3 | Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated April 5, 2024 | 8-K | 001-37465 | 3.1 | 4/8/24 | |
| 3.4 | Amended and Restated Bylaws | 8-K | 001-37465 | 3.1 | 1/2/24 | |
| 10.1# | Employment Agreement, dated February 24, 2024, by and between the Registrant and Marella Thorell | * | ||||
| 10.2# | Non-Employee Director Compensation Program | * | ||||
| 10.3# | Separation Agreement and Release, dated March 15, 2024, by and between the Registrant and David Arkowitz | * | ||||
| 10.4# | Advisory Agreement, dated March 15, 2024, by and between the Registrant and David Arkowitz | * | ||||
| 10.5† | Supply Agreement, dated September 15, 2015, by and between the Registrant and GenIbet BioPharmaceuticals, SA, as amended | * | ||||
| 10.6 | Form of Performance Option Agreement under the 2015 Incentive Award Plan | * | ||||
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer | * | ||||
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer | * | ||||
| 32.1 | Section 1350 Certification of Chief Executive Officer | ** | ||||
| 32.2 | Section 1350 Certification of Chief Financial Officer | ** | ||||
| 101.INS | Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document | * | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | * | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | * | ||||
- Filed herewith.
** Furnished herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.